Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Purchase individual online access for 1 year to this journal.
Price: EUR 185.00Authors: Jung, Friedrich | Pietzsch, Jens
Article Type: Editorial
DOI: 10.3233/CH-199101
Citation: Clinical Hemorheology and Microcirculation, vol. 73, no. 3, pp. 379-380, 2019
Authors: Rothe, Rebecca | Schulze, Sabine | Neuber, Christin | Hauser, Sandra | Rammelt, Stefan | Pietzsch, Jens
Article Type: Research Article
Abstract: Critical-size bone defects after compound fractures, infection, or tumor resection are challenging to treat. The same is true for fractures in patients with impaired bone healing due to metabolic diseases and cancer. Despite considerable progress over the last decade in surgical techniques, material design, and dedicated imaging approaches, these scenarios represent unsolved clinical problems. The high socioeconomic burden of such conditions justifies increasing interest in novel osteoinductive drugs for adjuvant therapeutic approaches. There is an increasing body of experimental and clinical literature on potentially promising effects of growth factors, anti-resorptive, and anabolic agents. The true clinical efficacy of these, however, …is discussed controversially. Therefore, we aimed to critically examine the hypothesis that targeted adjuvant therapies have the potential to enhance bone regeneration in critical-size bone defects and under systemic conditions that impair bone healing. This first approach to the topic deals with small molecule drugs and compounds that influence the immune response and inflammatory processes. In particular, literature reporting on selective cyclooxygenase-2 inhibitors has been reviewed with respect to their local and systemic mode of action and to stimulate further research on bone healing under critical conditions. Show more
Keywords: Biomaterials, critical-size bone defects, cyclooxygenase-2, innate immunity, prostanoids, signaling, small molecules
DOI: 10.3233/CH-199102
Citation: Clinical Hemorheology and Microcirculation, vol. 73, no. 3, pp. 381-408, 2019
Authors: Rothe, Rebecca | Schulze, Sabine | Neuber, Christin | Hauser, Sandra | Rammelt, Stefan | Pietzsch, Jens
Article Type: Research Article
Abstract: The treatment of critical-size bone defects following complicated fractures, infections or tumor resections is a major challenge. The same applies to fractures in patients with impaired bone healing due to systemic inflammatory and metabolic diseases. Despite considerable progress in development and establishment of new surgical techniques, design of bone graft substitutes and imaging techniques, these scenarios still represent unresolved clinical problems. However, the development of new active substances offers novel potential solutions for these issues. This work discusses therapeutic approaches that influence angiogenesis or hypoxic situations in healing bone and surrounding tissue. In particular, literature on sphingosine-1-phosphate receptor modulators and …nitric oxide (NO• ) donors, including bi-functional (hybrid) compounds like NO• -releasing cyclooxygenase-2 inhibitors, was critically reviewed with regard to their local and systemic mode of action. Show more
Keywords: Critical-size bone defects, neovascularization, nitric oxide donors, signaling, small molecules, sphingosine-1-phosphate receptor
DOI: 10.3233/CH-199103
Citation: Clinical Hemorheology and Microcirculation, vol. 73, no. 3, pp. 409-438, 2019
Authors: Rothe, Rebecca | Schulze, Sabine | Neuber, Christin | Hauser, Sandra | Rammelt, Stefan | Pietzsch, Jens
Article Type: Research Article
Abstract: In this third in a series of reviews on adjuvant drug-assisted bone healing, further approaches aiming at influencing the healing process are discussed. Local and systemic modulation of bone metabolism is pursued with use of a number of drugs with completely different indications, which are characterized by a pleiotropic spectrum of action. These include drugs used to treat lipid disorders (HMG-CoA reductase inhibitors), hypertension (ACE inhibitors), osteoporosis (bisphosphonates), cancer (proteasome inhibitors) and others. Potential applications to enhance bone healing are discussed.
Keywords: Bisphosphonates, bone metabolism, critical-size bone defects, small molecules, statins, strontium, Wnt signaling
DOI: 10.3233/CH-199104
Citation: Clinical Hemorheology and Microcirculation, vol. 73, no. 3, pp. 439-488, 2019
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl